We are remaining positive on the outlook of Supernus Pharmaceuticals' (NASDAQ:SUPN) shares after the Company released its 4Q13 and FY2013 results. Reported revenues for 2013 were approximately $12 million, which exceeded analyst estimates of $8.3 million. Shares of the company closed up 2.62% at $9.15 on March 12, 2014 on news about the potential of the company's marketed products.
(click to enlarge)
Supernus is a Rockville, Maryland-based specialty pharmaceutical company that is focused on the development and commercialization of products for the treatment of central nervous system diseases. The company has recently seen the launch of two products for the treatment of epilepsy, Oxtellar XR™ and Trokendi XR™, and has experienced solid adoption in the marketplace. In the...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|